A compound of Formula (I) 1
and pharmaceutically and/or veterinarily acceptable derivatives thereof,
wherein R.sup.1 is H, C.sub.1-6alkyl, --C(X)Y, C.sub.3-8cycloalkyl, aryl,
het, aryl-C.sub.1-4alkyl or het-C.sub.1-4alkyl, wherein the cycloalkyl,
aryl or het groups are optionally substituted by at least one substituent
independently selected from C.sub.1-8alkyl, C.sub.1-8alkoxy, OH, halo,
CF.sub.3, OCF.sub.3, SCF.sub.3, hydroxy-C.sub.1-6alkyl,
C.sub.1-4alkoxy-C.sub.1-6alkyl and C.sub.1-4alkyl-S--C.sub.1-4alkyl;
R.sup.2 is aryl or heteroaryl, each optionally substituted by at least
one substituent independently selected from C.sub.1-8alkyl,
C.sub.1-8alkoxy, OH, halo, CF.sub.3, OCF.sub.3, SCF.sub.3,
hydroxy-C.sub.1-6alkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl and
C.sub.1-4alkyl-S--C.sub.1-4alkyl; R.sup.3 is C.sub.1-6alkyl,
C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl-C.sub.1-6alkyl, aryl, het,
aryl-C.sub.1-4alkyl or het-C.sub.1-4alkyl, wherein the cycloalkyl, aryl
or het groups are optionally substituted by at least one substituent
independently selected from C.sub.1-6alkyl, C.sub.1-6alkoxy, OH, halo,
CF.sub.3, OCF.sub.3, SCF.sub.3, hydroxy-C.sub.1-6alkyl, C.sub.1-4alkoxy
--C.sub.1-6alkyl and C.sub.1-4alkyl-S--C.sub.1-4alkyl; X is S or O; Y is
H, C.sub.1-6alkyl, aryl, het, aryl-C.sub.1-4alkyl or het-C.sub.1-4alkyl;
and n is 1 or 2, provided that when n is 1, m is 0 or 1 and when n is 2,
m is 0, wherein if m is 0, then * represents a chiral center. The
compounds of the invention exhibit activity as both serotonin and
noradrenaline re-uptake inhibitors and therefore have utility in a
variety of therapeutic areas, for example urinary incontinence.
